The diagnostic process for prostate cancer has changed, but uncertainty remains about the harms to benefits ratio of prostate cancer screening. Natalia will explain how Real World Data has helped to bridge the evidence gap left by prostate cancer screening trials, and demonstrate how the reduction in harms can inform decisions about proactively offering PSA blood tests to patients at higher risk, and the future of prostate cancer screening.